IDEAYA Grants 221,000 Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: PRnewswire
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The stock options have an exercise price of $29.34 per share, which matches the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The granted stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions to IDEAYA.
- Company Overview: IDEAYA is a precision medicine oncology company focused on developing transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 29.340
Low
30.00
Averages
49.86
High
79.00
Current: 29.340
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Grants 221,000 Stock Options to New Employees
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The stock options have an exercise price of $29.34 per share, which matches the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The granted stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions to IDEAYA.
- Company Overview: IDEAYA is a precision medicine oncology company focused on developing transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
See More
IDEAYA Grants 221,000 Stock Options to New Employees
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees, aimed at attracting top talent to enhance the team’s capabilities in advancing precision medicine research.
- Incentive Plan Context: The grant is made under the 2023 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), specifically designed to attract individuals who were not previously employed by IDEAYA, ensuring the company can recruit industry-leading talent.
- Option Exercise Price: The stock options have an exercise price of $29.34 per share, equal to the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the grant date, aligning employee interests with those of shareholders.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions during their tenure with the company.
See More
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
- Trial Launch: On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in cancer treatment, particularly for patients with prostate, ovarian, and pancreatic cancers.
- FDA Approval: The IND application for GTB-5550 received FDA clearance in February 2026, with the trial structured as a basket trial prioritizing enrollment of advanced cancer patients who have failed prior therapies, demonstrating the company's commitment to addressing unmet medical needs.
- Strong Financial Position: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, thereby enhancing investor confidence in the progress of the clinical trial.
- Significant Market Potential: Targeting the estimated $362 billion global solid tumor market, the B7-H3 antigen has attracted multiple pharmaceutical companies, indicating a rapidly rising clinical translation potential in this competitive landscape.
See More
GT Biopharma Launches Clinical Trial for B7-H3 Targeted Therapy
- Trial Launch: GT Biopharma announced on May 14, 2026, that the first patient has been dosed in its Phase 1 dose-escalation trial of GTB-5550, a therapy targeting B7-H3 in solid tumors, marking a significant advancement in the company's oncology efforts.
- Innovative Targeting Mechanism: GTB-5550 is the third TriKE® molecule from GT Biopharma, utilizing subcutaneous administration to enhance patient convenience, particularly in prostate cancer where B7-H3 is expressed in over 90% of metastatic castration-resistant tumors.
- Market Potential Emerges: The rising interest in B7-H3 as an oncology target is underscored by GT Biopharma's trial progress alongside other companies like Summit Therapeutics and IDEAYA, indicating broad applicability of this target in cancer treatment.
- Strengthened Industry Collaborations: The partnership between Summit Therapeutics and GSK further validates the market value of B7-H3, with the combination study of GSK's antibody drug and Summit's bispecific antibody expected to begin in mid-2026, providing positive signals for investors.
See More
IDEAYA Biosciences Reports Q1 2026 Financial Results and Business Update
- Financial Overview: As of March 31, 2026, IDEAYA reported approximately $972.9 million in cash and cash equivalents, down from $1.05 billion as of December 31, 2025, primarily due to increased net cash used in operations, indicating pressure on the company's financial management.
- Collaboration Revenue Decline: Collaboration revenue for Q1 2026 totaled $6.6 million, significantly down from $10.9 million in Q4 2025, reflecting reduced revenue from R&D services under the exclusive license agreement with Servier, which may impact future cash flow and project progress.
- R&D Expenses Increase: R&D expenses reached $95.7 million in Q1 2026, up from $86.6 million in Q4 2025, driven by higher clinical trial and personnel-related costs, indicating the company's ongoing investment in advancing its product pipeline.
- Widening Net Loss: The net loss for Q1 2026 was $98.5 million, compared to a loss of $83.3 million in Q4 2025, reflecting high costs associated with expanding R&D and market preparation, which could negatively affect investor confidence.
See More
IDEAYA Grants Stock Options to New Employees
- Stock Option Grant: On April 30, 2026, IDEAYA granted 237,800 non-qualified stock options to five new employees, aimed at attracting top talent and strengthening the team.
- Incentive Plan Context: The grant is made under the 2023 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), specifically designed to attract individuals who were not previously employed by IDEAYA.
- Option Exercise Price: The stock options have an exercise price of $29.10 per share, equal to the closing price of IDEAYA's common stock on the grant date, ensuring alignment of employee interests with company stock performance.
- Vesting Arrangement: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, incentivizing continued employee service and contribution to the company.
See More
IDEAYA Grants 221,000 Stock Options to New Employees
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees as an inducement for joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The stock options have an exercise price of $29.34 per share, which matches the closing price of IDEAYA's common stock on the grant date, aligning employee interests with the company's stock performance.
- Vesting Schedule: The granted stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions to IDEAYA.
- Company Overview: IDEAYA is a precision medicine oncology company focused on developing transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
See More
IDEAYA Grants 221,000 Stock Options to New Employees
- Stock Option Grant: On May 28, 2026, IDEAYA granted 221,000 non-qualified stock options to six newly hired employees, aimed at attracting top talent to enhance the team’s capabilities in advancing precision medicine research.
- Incentive Plan Context: The grant is made under the 2023 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), specifically designed to attract individuals who were not previously employed by IDEAYA, ensuring the company can recruit industry-leading talent.
- Option Exercise Price: The stock options have an exercise price of $29.34 per share, equal to the closing price of IDEAYA's common stock on the Nasdaq Global Select Market on the grant date, aligning employee interests with those of shareholders.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years, ensuring ongoing employee contributions during their tenure with the company.
See More
GT Biopharma Doses First Patient in GTB-5550 Clinical Trial
- Trial Launch: On May 14, 2026, GT Biopharma dosed the first patient in its Phase 1 trial for GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in cancer treatment, particularly for patients with prostate, ovarian, and pancreatic cancers.
- FDA Approval: The IND application for GTB-5550 received FDA clearance in February 2026, with the trial structured as a basket trial prioritizing enrollment of advanced cancer patients who have failed prior therapies, demonstrating the company's commitment to addressing unmet medical needs.
- Strong Financial Position: As of March 31, 2026, GT Biopharma reported a cash balance of approximately $9 million, anticipated to sustain operations through Q4 2026, thereby enhancing investor confidence in the progress of the clinical trial.
- Significant Market Potential: Targeting the estimated $362 billion global solid tumor market, the B7-H3 antigen has attracted multiple pharmaceutical companies, indicating a rapidly rising clinical translation potential in this competitive landscape.
See More
GT Biopharma Launches Clinical Trial for B7-H3 Targeted Therapy
- Trial Launch: GT Biopharma announced on May 14, 2026, that the first patient has been dosed in its Phase 1 dose-escalation trial of GTB-5550, a therapy targeting B7-H3 in solid tumors, marking a significant advancement in the company's oncology efforts.
- Innovative Targeting Mechanism: GTB-5550 is the third TriKE® molecule from GT Biopharma, utilizing subcutaneous administration to enhance patient convenience, particularly in prostate cancer where B7-H3 is expressed in over 90% of metastatic castration-resistant tumors.
- Market Potential Emerges: The rising interest in B7-H3 as an oncology target is underscored by GT Biopharma's trial progress alongside other companies like Summit Therapeutics and IDEAYA, indicating broad applicability of this target in cancer treatment.
- Strengthened Industry Collaborations: The partnership between Summit Therapeutics and GSK further validates the market value of B7-H3, with the combination study of GSK's antibody drug and Summit's bispecific antibody expected to begin in mid-2026, providing positive signals for investors.
See More
IDEAYA Biosciences Reports Q1 2026 Financial Results and Business Update
- Financial Overview: As of March 31, 2026, IDEAYA reported approximately $972.9 million in cash and cash equivalents, down from $1.05 billion as of December 31, 2025, primarily due to increased net cash used in operations, indicating pressure on the company's financial management.
- Collaboration Revenue Decline: Collaboration revenue for Q1 2026 totaled $6.6 million, significantly down from $10.9 million in Q4 2025, reflecting reduced revenue from R&D services under the exclusive license agreement with Servier, which may impact future cash flow and project progress.
- R&D Expenses Increase: R&D expenses reached $95.7 million in Q1 2026, up from $86.6 million in Q4 2025, driven by higher clinical trial and personnel-related costs, indicating the company's ongoing investment in advancing its product pipeline.
- Widening Net Loss: The net loss for Q1 2026 was $98.5 million, compared to a loss of $83.3 million in Q4 2025, reflecting high costs associated with expanding R&D and market preparation, which could negatively affect investor confidence.
See More
IDEAYA Grants Stock Options to New Employees
- Stock Option Grant: On April 30, 2026, IDEAYA granted 237,800 non-qualified stock options to five new employees, aimed at attracting top talent and strengthening the team.
- Incentive Plan Context: The grant is made under the 2023 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), specifically designed to attract individuals who were not previously employed by IDEAYA.
- Option Exercise Price: The stock options have an exercise price of $29.10 per share, equal to the closing price of IDEAYA's common stock on the grant date, ensuring alignment of employee interests with company stock performance.
- Vesting Arrangement: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, incentivizing continued employee service and contribution to the company.
See More
